Related Experiment Video
Updated: Jan 19, 2026

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
Published on: October 17, 2025
Improving Response to FLT3 Inhibitors-BCL2 the Rescue?
1Division of Hematology-Oncology, Perelman School of Medicine and the Abramson Cancer Center at the University of Pennsylvania, Philadelphia, Pennsylvania. alexander.perl@uphs.upenn.edu.
Abstract:
As single agents, FLT3 inhibitors are active in FLT3-mutated acute myeloid leukemia (AML) therapy but not curative. The BCL2 inhibitor, venetoclax, enhances responses to low intensity AML chemotherapy but its activity is limited by MCL1 upregulation. FLT3 inhibitors downregulate MCL1 and synergize with venetoclax in preclinical AML models.See related article by Ma et al., p. 6815.
Related Concept Videos
04:36Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:46A Novel Rescue Technique for Difficult Intubation and Difficult Ventilation
10:55Rescue of Recombinant Newcastle Disease Virus from cDNA
Eukaryotic Transcription Inhibitors
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
04:38A Novel Technique of Rescuing Capsulorhexis Radial Tear-out using a Cystotome
06:42Identifying Kinase Inhibitors that Modulate the Thymocyte Response to Strong TCR Signals

